Literature DB >> 31059681

Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.

Matthew Egyud1, Mohamedtaki Tejani2, Arjun Pennathur3, James Luketich3, Praveen Sridhar1, Emiko Yamada1, Anders Ståhlberg4, Stefan Filges4, Paul Krzyzanowski5, Jennifer Jackson1, Irina Kalatskaya5, Wei Jiao5, Gradon Nielsen2, Zhongren Zhou6, Virginia Litle1, Lincoln Stein5, Tony Godfrey7.   

Abstract

BACKGROUND: Recent literature has demonstrated the potential of "liquid biopsy" and detection of circulating tumor (ct)DNA as a cancer biomarker. However, to date there is a lack of data specific to esophageal adenocarcinoma (EAC). This study was conducted to determine how detection and quantification of ctDNA changes with disease burden in patients with EAC and evaluate its potential as a biomarker in this population.
METHODS: Blood samples were obtained from patients with stage I to IV EAC. Longitudinal blood samples were collected from a subset of patients. Imaging studies and pathology reports were reviewed to determine disease course. Tumor samples were sequenced to identify mutations. Mutations in plasma DNA were detected using custom, barcoded, patient-specific sequencing libraries. Mutations in plasma were quantified, and associations with disease stage and response to therapy were explored.
RESULTS: Plasma samples from a final cohort of 38 patients were evaluated. Baseline plasma samples were ctDNA positive for 18 patients (47%) overall, with tumor allele frequencies ranging from 0.05% to 5.30%. Detection frequency of ctDNA and quantity of ctDNA increased with stage. Data from longitudinal samples indicate that ctDNA levels correlate with and precede evidence of response to therapy or recurrence.
CONCLUSIONS: ctDNA can be detected in plasma of EAC patients and correlates with disease burden. Detection of ctDNA in early-stage EAC is challenging and may limit diagnostic applications. However, our data demonstrate the potential of ctDNA as a dynamic biomarker to monitor treatment response and disease recurrence in patients with EAC.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31059681      PMCID: PMC6676214          DOI: 10.1016/j.athoracsur.2019.04.004

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  29 in total

1.  Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing.

Authors:  Emmanuele Abate; Steven R DeMeester; Joerg Zehetner; Arzu Oezcelik; Shahin Ayazi; Jesse Costales; Farzaneh Banki; John C Lipham; Jeffrey A Hagen; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

2.  Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

Authors:  L N Mathieu; N F Kanarek; H-L Tsai; C M Rudin; M V Brock
Journal:  Dis Esophagus       Date:  2013-10-07       Impact factor: 3.429

3.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

4.  Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients.

Authors:  Giuseppe Portale; Jeffrey A Hagen; Jeffrey H Peters; Linda S Chan; Steven R DeMeester; Tasha A K Gandamihardja; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2006-04       Impact factor: 6.113

5.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  A survey of oesophageal cancer: pathology, stage and clinical presentation.

Authors:  B Schlansky; A J Dimarino; D Loren; A Infantolino; T Kowalski; S Cohen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-01       Impact factor: 8.171

7.  High fragmentation characterizes tumour-derived circulating DNA.

Authors:  Florent Mouliere; Bruno Robert; Erika Arnau Peyrotte; Maguy Del Rio; Marc Ychou; Franck Molina; Celine Gongora; Alain R Thierry
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

8.  Paired exome analysis of Barrett's esophagus and adenocarcinoma.

Authors:  Matthew D Stachler; Amaro Taylor-Weiner; Shouyong Peng; Aaron McKenna; Agoston T Agoston; Robert D Odze; Jon M Davison; Katie S Nason; Massimo Loda; Ignaty Leshchiner; Chip Stewart; Petar Stojanov; Sara Seepo; Michael S Lawrence; Daysha Ferrer-Torres; Jules Lin; Andrew C Chang; Stacey B Gabriel; Eric S Lander; David G Beer; Gad Getz; Scott L Carter; Adam J Bass
Journal:  Nat Genet       Date:  2015-07-20       Impact factor: 38.330

9.  Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.

Authors:  Austin M Dulak; Petar Stojanov; Shouyong Peng; Michael S Lawrence; Cameron Fox; Chip Stewart; Santhoshi Bandla; Yu Imamura; Steven E Schumacher; Erica Shefler; Aaron McKenna; Scott L Carter; Kristian Cibulskis; Andrey Sivachenko; Gordon Saksena; Douglas Voet; Alex H Ramos; Daniel Auclair; Kristin Thompson; Carrie Sougnez; Robert C Onofrio; Candace Guiducci; Rameen Beroukhim; Zhongren Zhou; Lin Lin; Jules Lin; Rishindra Reddy; Andrew Chang; Rodney Landrenau; Arjun Pennathur; Shuji Ogino; James D Luketich; Todd R Golub; Stacey B Gabriel; Eric S Lander; David G Beer; Tony E Godfrey; Gad Getz; Adam J Bass
Journal:  Nat Genet       Date:  2013-03-24       Impact factor: 38.330

10.  Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy.

Authors:  W R C Knight; J Zylstra; M Van Hemelrijck; N Griffin; A E T Jacques; N Maisey; C R Baker; J A Gossage; J Largergren; A R Davies
Journal:  BJS Open       Date:  2018-03-15
View more
  13 in total

1.  Don't Anger the Host: New Etiquette in Standard Cancer Assessment?

Authors:  Kei Suzuki; Virginia R Litle
Journal:  Ann Surg Oncol       Date:  2020-10-27       Impact factor: 5.344

2.  Systematic evaluation of cell-type deconvolution pipelines for sequencing-based bulk DNA methylomes.

Authors:  Yunhee Jeong; Lisa Barros de Andrade E Sousa; Dominik Thalmeier; Reka Toth; Marlene Ganslmeier; Kersten Breuer; Christoph Plass; Pavlo Lutsik
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

3.  Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.

Authors:  Carlos S Cabalag; Michael Yates; Mariana Benitez Corrales; Paul Yeh; Stephen Q Wong; Bonnie Z Zhang; Kenji M Fujihara; Lynn Chong; Michael W Hii; Sarah-Jane Dawson; Wayne A Phillips; Cuong P Duong; Nicholas J Clemons
Journal:  Ann Surg       Date:  2021-08-20       Impact factor: 13.787

4.  Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy.

Authors:  Roberta La Mendola; Maria Bencivenga; Lorena Torroni; Luca Alberti; Michele Sacco; Francesco Casella; Cecilia Ridolfi; Nicola Simoni; Renato Micera; Michele Pavarana; Giuseppe Verlato; Simone Giacopuzzi
Journal:  Ann Surg Oncol       Date:  2020-10-19       Impact factor: 5.344

Review 5.  Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation.

Authors:  Tania Triantafyllou; Bas Wijnhoven
Journal:  Ann Gastroenterol Surg       Date:  2020-07-25

Review 6.  Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring.

Authors:  Ivana Martins; Ilda Patrícia Ribeiro; Joana Jorge; Ana Cristina Gonçalves; Ana Bela Sarmento-Ribeiro; Joana Barbosa Melo; Isabel Marques Carreira
Journal:  Genes (Basel)       Date:  2021-02-27       Impact factor: 4.096

7.  Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients.

Authors:  Karin Wallander; Jesper Eisfeldt; Mats Lindblad; Daniel Nilsson; Kenny Billiau; Hassan Foroughi; Magnus Nordenskjöld; Agne Liedén; Emma Tham
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

Review 8.  A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer.

Authors:  Jiang Min; Huilin Zhou; Su Jiang; Hong Yu
Journal:  Med Sci Monit       Date:  2022-02-25

9.  Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.

Authors:  Mina Gaga; Joanna Chorostowska-Wynimko; Ildikó Horváth; Martin C Tammemagi; David Shitrit; Vered H Eisenberg; Hao Liang; David Stav; Dan Levy Faber; Maarten Jansen; Yael Raviv; Vasileios Panagoulias; Piotr Rudzinski; Gabriel Izbicki; Ohad Ronen; Adiv Goldhaber; Rawia Moalem; Nadir Arber; Ilana Haas; Qinghua Zhou
Journal:  Eur Respir J       Date:  2021-01-14       Impact factor: 16.671

Review 10.  Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?

Authors:  Zuyang Yuan; Xinfeng Wang; Xiao Geng; Yin Li; Juwei Mu; Fengwei Tan; Qi Xue; Shugeng Gao; Jie He
Journal:  Cancer Commun (Lond)       Date:  2020-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.